Opioid-induced constipation (OIC) is a frequent adverse event among patients receiving chronic pain therapy that is requiring opioids. Naldemedine was approved by the Food and Drug Administration to treat OIC and appears to be more efficient than any other peripherally acting 碌-opioid receptor antagonist. This meta-analysis aimed at assessing the available data on naldemedine in terms of efficacy.
Browse by Audience
